• Estradiol Workflows for ER–Autophagy Research

  2026-09-02

  Build reproducible 17 beta-estradiol experiments that connect receptor signaling, autophagy, and tissue-protection readouts. This practical workflow moves beyond single-gene assays by combining dose–time optimization, receptor dissection, and multi-organ validation.

• 2-Hydroxypropyl-β-cyclodextrin Workflow Guide

  2026-09-02

  2-Hydroxypropyl-β-cyclodextrin is a practical solubilizer for poorly water-soluble, hydrophobic compounds, especially molecules containing aromatic or phenyl groups. It is appropriate for pharmaceutical and biochemical solubility workflows and drug formulation excipient screening, but the available dossier does not establish clinical performance, pharmacokinetic benefit, or suitability for unrelated applications.

• Anti-Inflammatory Airway Stents Against TISR

  2026-09-01

  Zhao and colleagues developed PAGL, an electrospun airway stent combining anlotinib hydrochloride with silver nanoparticles to address infection, inflammation, angiogenesis, and fibroblast activation in tracheal in-stent restenosis. In a rabbit model, the multifunctional stent reduced pathological responses and downregulated gene programs linked to fibrosis, intimal hyperplasia, and cell migration, supporting a microenvironment-focused strategy for airway-stent design.

• L-Phenylephrine: A Sex-Aware Assay Framework

  2026-09-01

  L-Phenylephrine is an adrenergic α1A receptor agonist suited to dissecting receptor signaling, vascular responses, and cardiomyocyte phenotypes. This guide uses telemetry, baroreflex, and gonadectomy findings from an angiotensin II hypertension study to improve assay design and interpretation.

• Separating Cell Arrest from Death in Cancer Drug Assays

  2026-08-31

  Hannah Schwartz’s 2022 dissertation shows that relative viability and fractional viability capture different dimensions of cancer drug response and should not be treated as interchangeable endpoints. The work provides a practical framework for distinguishing proliferative arrest from cell killing, improving interpretation of in vitro drug screens and combination studies.

• Neomycin Sulfate: From Structure to Assay Design

  2026-08-31

  Neomycin sulfate is an aminoglycoside antibiotic whose effects on RNA, DNA, and ion channels depend strongly on molecular context. This guide connects its mechanistic profile with assay design and uses a recent allergic-rhinitis preprint to explain how antibiotic perturbations should be interpreted without overextending the evidence.

• Amitriptyline HCl: Protocols and QC

  2026-08-30

  Amitriptyline HCl (SKU B2231) provides a defined small-molecule tool for receptor modulation studies when researchers need a documented multi-receptor pharmacology profile and practical handling specifications. It is appropriate for controlled neuropharmacology workflows, but it should not be treated as a selective probe, a clinical treatment, or a substitute for directly matched paper evidence.

• Dihydrotestosterone Workflows for AR Research

  2026-08-29

  Build controlled DHT experiments that connect androgen receptor activation with EGFR, ERBB2, AKT, and ERK readouts in cancer models. The workflow also shows how to translate these assays into resistance studies and, with appropriate caution, muscle and ALS research.

• L-Phenylephrine: Translational α1A Signaling

  2026-08-28

  L-Phenylephrine provides a focused chemical entry point into α1-adrenergic receptor signaling, linking vascular responses with cardiac survival, gene regulation, and neural progenitor biology. This thought-leadership guide shows how to use the compound strategically in sex-aware cardiovascular models while preserving the distinction between mechanistic evidence, workflow recommendations, and translational hypotheses.

• Modeling Breast Cancer Relapse with Proliferation Tracing

  2026-08-28

  The reference study introduces a dual recombinase proliferation-tracing and ablation system in MMTV-PyMT mice to model relapse after preferential loss of rapidly dividing tumor cells. Ablation caused marked tumor regression followed by recurrence from residual low-cycling cells, while single-cell RNA sequencing revealed stem-like and immunological features associated with aggressive recurrent disease.

• Reframing ER Modulation in Breast Cancer Relapse

  2026-08-27

  Translational breast cancer research increasingly requires two complementary views: how estrogen receptor ligands alter tumor-cell signaling and how residual, low-cycling populations rebuild a tumor after treatment. This article connects (Z)-4-Hydroxytamoxifen pharmacology with a recent proliferation-tracing relapse model, clarifying where the approaches align, where they must remain experimentally distinct, and how to design more informative preclinical studies.

• Estradiol Workflows for Receptor–Autophagy Studies

  2026-08-27

  Build more interpretable hormone-response experiments with Estradiol by combining receptor-aware dosing, autophagy measurements, and solvent controls. This workflow translates multi-organ protection findings into practical cell and tissue assay decisions while highlighting handling and troubleshooting steps.

• METTL17, Mitochondrial Translation, and Ferroptosis

  2026-08-26

  The reference study identifies METTL17 as a mitochondrial defense factor that promotes ferroptosis resistance and colorectal cancer progression by sustaining mitochondrial RNA methylation and translation. Its findings connect mitochondrial epitranscriptomic regulation with lipid peroxidation, tumor growth, and ferroptosis-based therapeutic sensitization.

• Erlotinib (NSC 718781): EGFR Research Guide

  2026-08-26

  Erlotinib (NSC 718781) is an orally bioavailable EGFR tyrosine kinase inhibitor that competitively targets the intracellular ATP-binding site. Its biochemical and cellular potency supports EGFR pathway studies, while recent evidence indicates that EGFR-CXCR4 receptor complexes can reshape signaling context.

• Cyclo (-RGDfC): From Integrin Biology to Translation

  2026-08-25

  A translational perspective on how Cyclo (-RGDfC) and c(RGDfC) can connect αvβ3 integrin biology with tumor targeting, angiogenesis research, and mechanistic cancer studies, while keeping evidence, assay design, and product use clearly separated.

8197 records 4/547 page Previous Next 12345 下5页 Last page